Document Detail


Angiotensin-converting enzyme inhibition with spirapril in patients with coronary artery disease.
MedLine Citation:
PMID:  8061851     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In a randomized double-blind, placebo-controlled, crossover trial, the potential anti-ischaemic action of the angiotensin-converting enzyme (ACE) inhibitor spirapril was studied in 19 patients with coronary artery disease (CAD) and reproducible exercise-induced ST-segment depression, but without hypertension or congestive heart failure. Measurements of blood pressure and heart rate as well as exercise-testing were performed after 2 weeks of treatment each with placebo and spirapril. Anginal attacks and consumption of short-acting nitrates were recorded in the patients' diaries. Resting blood pressure was not significantly reduced (143 +/- 20/89 +/- 10 mmHg vs 138 +/- 17/87 +/- 10 mmHg). The exercise-induced ST-segment depression, the main criterion for anti-ischaemic effect, was 2.17 +/- 1.72 mm after placebo and not significantly affected by spirapril (2.03 +/- 1.47 mm) despite a significant reduction in blood pressure x heart rate product at maximum workload (213 +/- 45.4 vs 197.5 +/- 36.8; p < 0.05). The number of anginal attacks per week and nitrate consumption remained virtually unchanged. A significant reduction of exercise-induced ischaemia in normotensive patients with CAD was not demonstrated with spirapril.
Authors:
P Thürmann; N Rietbrock
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Blood pressure. Supplement     Volume:  2     ISSN:  0803-8023     ISO Abbreviation:  Blood Press Suppl     Publication Date:  1994  
Date Detail:
Created Date:  1994-09-22     Completed Date:  1994-09-22     Revised Date:  2008-02-26    
Medline Journal Info:
Nlm Unique ID:  9300787     Medline TA:  Blood Press Suppl     Country:  NORWAY    
Other Details:
Languages:  eng     Pagination:  73-6     Citation Subset:  IM    
Affiliation:
Department of Clinical Pharmacology, University Clinic Frankfurt, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Blood Pressure / drug effects
Coronary Disease / drug therapy*,  physiopathology
Double-Blind Method
Electrocardiography / drug effects
Enalapril / analogs & derivatives*,  therapeutic use
Exercise Test
Heart Rate / drug effects
Humans
Middle Aged
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 75847-73-3/Enalapril; 83647-97-6/spirapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Spirapril: pharmacokinetic properties and drug interactions.
Next Document:  A multicentre multidose study of the efficacy and safety of spirapril in mild-to-moderate essential ...